In vitro and in vivo activities of anti-influenza virus compound T-705.
about
The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymeraseStructure and functionality in flavivirus NS-proteins: perspectives for drug designT-705 (favipiravir) inhibition of arenavirus replication in cell cultureCurrent and future antiviral therapy of severe seasonal and avian influenzaManagement of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignanciesProgress in the experimental therapy of severe arenaviral infectionsEvaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic feverActivity of T-1106 in a Hamster Model of Yellow Fever Virus InfectionIn Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus InfectionsEfficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodentsActivity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106Effect of T-705 treatment on western equine encephalitis in a mouse modelApproved Antiviral Drugs over the Past 50 YearsThe Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug DesignCompounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virusTreatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirinEffective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic FeverMultiscale modeling of influenza A virus infection supports the development of direct-acting antiviralsCoronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeuticsFavipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic feverEstablishment of a High-Throughput Assay to Monitor Influenza A Virus RNA Transcription and ReplicationA Novel Antiviral Target Structure Involved in the RNA Binding, Dimerization, and Nuclear Export Functions of the Influenza A Virus NucleoproteinExperimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaEmergence and pandemic potential of swine-origin H1N1 influenza virusIn vitro and in vivo characterization of new swine-origin H1N1 influenza virusesPandemic and seasonal influenza: therapeutic challengesProgress of small molecular inhibitors in the development of anti-influenza virus agents.Challenges and opportunities in developing respiratory syncytial virus therapeuticsSynergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice.Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.Drugs in development for influenza.Influenza antivirals currently in late-phase clinical trial.ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.Combination chemotherapy for influenza.Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase.T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitroPhenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors
P2860
Q21089768-B31E9463-2748-4D50-BBAE-ECB198272C0EQ23011530-7FAB17DC-A3FA-473F-AFF1-933F7280F1D8Q24633241-C82E5EA7-D479-43AE-BB01-973BC0F571F1Q24656164-862CD8BC-42A8-45E7-915B-FD3A1D7F7153Q26853131-9F9EC98F-A0B7-419B-B441-24825F419B28Q27024953-41126B68-EC11-4D0A-9BB4-096F941E108FQ27457152-391A55DA-B9B1-432A-8961-FA0F4A34DF11Q27480272-9D60C893-718C-4234-97BD-173435EB8C55Q27481401-A3877325-9DDE-491E-88D6-AC88B3C664ACQ27487357-F72FE05D-5CDD-4426-9B85-60A89C053552Q27487527-9F63DFB2-4A2E-4F85-81B2-DE17FB6A7540Q27488864-9BD19C73-F79B-4595-A49D-7A7A1997CBBCQ27755387-CBE236F6-7BC3-43AA-B233-731C684622FCQ28071809-46D9ECAF-89B3-4B7B-8DB0-DEAF2EE3CC7AQ28084005-17BC29F5-331E-4B67-A732-706A9DB37D38Q28474006-09E93A1A-AE0B-4EE3-8A31-C5456C913853Q28477434-90624318-FADD-4424-BD6E-2F0D41A6EE21Q28535330-45D281B7-48F0-49BD-8676-5CA303A5EBE2Q28535361-D0473A80-5792-4947-B4A1-76A90F495B42Q28537976-7F31BF8A-6C8A-416A-960D-76BAA1B26DE1Q28546724-DAF19535-556A-4BEC-A132-1C74AA64D229Q28546866-5C8965CD-45A2-460B-9D40-7BD4B23E3170Q28550455-F962CE47-257E-4C03-8A5A-98C9A1668406Q29619003-A46815CF-6875-4D2B-BA4D-8A957F03E1C0Q29619174-F9EA1E20-44C8-4AC3-B509-6B457E63B2C4Q30228856-0CA020F1-1297-44AB-BB49-0C65CC99AAB2Q30234943-AA4658F5-9C88-446A-98F8-5AC8A0755B21Q30300567-E4CDB21A-99CF-4A83-BB7A-D6F42CAE8554Q30359363-4614D9DA-85B2-4DFA-BBF8-BFFEEFC2202BQ30364319-256A1765-8D15-4650-BD63-41DBCAB295E5Q30387420-C19A681B-BA9A-4F06-8374-A61A03129CE0Q30391218-A853F925-443D-43A1-BA29-2D0CEC87AEE8Q30398099-A4671046-FF28-4E98-B3AD-C48739A6E5E9Q30404586-89628659-1D4E-4B1C-B6FA-F359D899BC19Q30407184-88D2E25C-13F4-4699-B69E-1B4525117CB5Q30408112-B1855F0A-0958-4AB3-9619-D32A6FC84ADFQ30414428-E5AEBAF8-5458-487D-8989-634DFC15298DQ30414976-3C33F7CE-1C78-4F76-96F3-D7F4D0AAC50BQ30426020-909D8BA3-6700-4CE2-9054-4227B294EE2DQ30450742-4BA4F452-3F90-4DEA-AD55-24E0825E1B1D
P2860
In vitro and in vivo activities of anti-influenza virus compound T-705.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
In vitro and in vivo activities of anti-influenza virus compound T-705.
@en
In vitro and in vivo activities of anti-influenza virus compound T-705.
@nl
type
label
In vitro and in vivo activities of anti-influenza virus compound T-705.
@en
In vitro and in vivo activities of anti-influenza virus compound T-705.
@nl
prefLabel
In vitro and in vivo activities of anti-influenza virus compound T-705.
@en
In vitro and in vivo activities of anti-influenza virus compound T-705.
@nl
P2093
P2860
P1476
In vitro and in vivo activities of anti-influenza virus compound T-705.
@en
P2093
K Takahashi
T Kamiyama
P2860
P304
P356
10.1128/AAC.46.4.977-981.2002
P407
P577
2002-04-01T00:00:00Z